Direct DNA Therapeutics
DNA as the active pharmaceutical ingredient for vaccinations and therapeutics is enabling rapid, versatile, stable, targeted and cost-effective therapies
Advantages of dbDNA™
dbDNA™ constructs are an optimal active pharmaceutical ingredient for the next generation of direct DNA therapeutics. Key benefits of dbDNA™ include:
Removal of antibiotic resistance dbDNA™ eliminates antibiotic selection markers present in pDNA and risk of delivering unwanted sequences.
Commercial scale dbDNA™ is linearly scalable through the multi-gram scale and because it is in vitro, is not susceptible to yield loss when amplifying complicated secondary structures e.g. direct repeats, homopolymeric stretches.
Rapid process for speed market cGMP dbDNA™ production is a two-week process, including QC.
Significant cost reduction Scaled cGMP dbDNA™ production costs are an order of magnitude less that pDNA.
Therapeutic DNA vaccines
Expression of an antigen via direct administration of DNA in order to elicit an immune response to a pathogen or tumour marker.
Prophylactic DNA vaccines
Expression of an antigen via direct administration of DNA in order to elicit a preventative immune response to infectious disease.
DNA monoclonal antibodies
Direct DNA administration to express a monoclonal antibody (mAb) that binds disease targets of therapeutic importance.
Non-viral gene therapies
Direct administration of DNA to correct diseases caused by faulty gene expression.